PCVX
Vaxcyte, Inc.
A clinical-stage biotech making vaccines with its XpressCF cell-free protein synthesis platform, which builds conjugate shots without the immune-dampening carrier proteins that limit conventional pneumococcal vaccines. Its lead candidates, VAX-31 and VAX-24, aim at pneumococcal disease in adults and children, and its pipeline also covers strep and shigellosis. The company gained control of its cell-free extract manufacturing through an agreement with Sutro Biopharma.
CUSIP: 92243G108HealthcareUS2 holders
Total Value
$64.33M
Total Shares
1.39M
Net Share Change
+64.7K
Activity
1 buying
Investor
Value
Shares
Weight
Change
